Telomir Pharma publishes preclinical data showing Telomir-Zn reverses insulin resistance in T2DM zebrafish model

Telomir Pharmaceuticals, Inc.

Telomir-Zn reduced HOMA-IR from ~10-12 to ~3 after 14 days in diet-induced T2DM zebrafish model.
Treatment produced dose-dependent improvements in fasting glucose, glucose tolerance, and fasting insulin levels.
This is the second peer-reviewed publication on Telomir-Zn in 2026, supporting its metal-homeostasis mechanism.
Telomir-Zn has FDA IND clearance for a Phase 1/2 trial in triple-negative breast cancer (TELO-001).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.